Stock Events

Stock Events

Actinogen Medical Limited 

$0.035000
7
-$0.00-0% Thursday 17:10

Statistics

Day High
0.035
Day Low
0.035
52W High
0.04
52W Low
0.0008
Volume
50,000
Avg. Volume
3,668
Mkt Cap
111.54M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

27AugExpected
Q2 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
-0.01
-0
-0
-0
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-9.37MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company is involved in the development of drugs that target central nervous system disorders, including Alzheimer's, similar to Actinogen's focus.
Biogen
BIIB
Mkt Cap32.28B
Biogen Inc. focuses on neurodegenerative diseases and has multiple products in Alzheimer's disease treatment, directly competing with Actinogen's Xanamem.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. has a strong portfolio in developing treatments for Alzheimer's disease, which competes with Actinogen's therapeutic areas.
Anavex Life Sciences
AVXL
Mkt Cap277.16M
Anavex Life Sciences Corp. specializes in Alzheimer's disease treatments using sigma-1 receptor agonists, a similar area of neurological focus.
AC Immune SA
ACIU
Mkt Cap263.48M
AC Immune SA develops therapies for Alzheimer's disease, directly competing with Actinogen's approach to cognitive impairment.
Acumen Pharmaceuticals
ABOS
Mkt Cap211.17M
Acumen Pharmaceuticals, Inc. is directly involved in Alzheimer's disease research, targeting amyloid beta oligomers, a common target in Alzheimer's therapy.

About

Actinogen Medical Limited is an Australian biotechnology firm specializing in the creation of treatments for neurological and neuropsychiatric conditions linked to abnormal brain cortisol levels. Their primary therapeutic candidate, Xanamem, functions as an inhibitor of the 11ß-HSD1 enzyme. Currently in Phase 2 clinical trials, Xanamem has shown the ability to engage its intended target within the central nervous system. Its development focuses on addressing Alzheimer's disease, cognitive impairment associated with depression, and the anxiety, sleep, and behavioral challenges seen in fragile X syndrome. Founded in 1999, the company, based in Sydney, Australia, operated as Actinogen Limited until its name change to Actinogen Medical Limited in November 2015.
Show more...
CEO
Steven G. Gourlay
Employees
6
Country
Australia
ISIN
AU000000ACW3
WKN
000A0MZH8

Listings

OTC Link
US
ATGGF
F
DE
3AC.F
AU
AU
ACW.AU

0 Comments

Share your thoughts

FAQ

What is Actinogen Medical Limited stock price today?▼
The current price of ATGGF is $0.04 USD — it has decreased by -0% in the past 24 hours. Watch Actinogen Medical Limited stock price performance more closely on the chart.
What is Actinogen Medical Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Actinogen Medical Limited stocks are traded under the ticker ATGGF.
Is Actinogen Medical Limited stock price growing?▼
ATGGF stock has risen by +0% compared to the previous week, the month change is a +4,275% rise, over the last year Actinogen Medical Limited has showed a +40% increase.
What is Actinogen Medical Limited market cap?▼
Today Actinogen Medical Limited has the market capitalization of 111.54M
When is the next Actinogen Medical Limited earnings date?▼
Actinogen Medical Limited is going to release the next earnings report on February 24, 2027.
What is Actinogen Medical Limited revenue for the last year?▼
Actinogen Medical Limited revenue for the last year amounts to 0 USD.
What is Actinogen Medical Limited net income for the last year?▼
ATGGF net income for the last year is -9.37M USD.
How many employees does Actinogen Medical Limited have?▼
As of September 06, 2026, the company has 6 employees.
In which sector is Actinogen Medical Limited located?▼
Actinogen Medical Limited operates in the Health & Wellness sector.
When did Actinogen Medical Limited complete a stock split?▼
The last stock split for Actinogen Medical Limited was on December 06, 2017 with a ratio of 17:15.
Where is Actinogen Medical Limited headquartered?▼
Actinogen Medical Limited is headquartered in Sydney, Australia.